Company Overview
Pacira BioSciences, Inc. operates within the healthcare sector, specifically focusing on the drug manufacturers industry for specialty and generic pharmaceuticals, where it develops, manufactures, markets, distributes, and sells non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company's primary product offering includes EXPAREL, a bupivacaine liposome injectable suspension designed for post-surgical applications, positioning it as a specialized player in the pain management landscape. In terms of scale, Pacira BioSciences holds a market capitalization of $970.13M and generates annual revenue of $726.41M, supported by a workforce of 825 employees. These valuation and revenue figures indicate that the company maintains a mid-cap presence in the healthcare market, reflecting a substantial operational footprint while operating with a relatively lean employee count compared to larger diversified pharmaceutical giants.
Financial Health
The company reported revenue of $726.41M for the trailing twelve months, resulting in a net income of $7.03M and an EBITDA of $124.33M. The significant gap between the reported revenue and net income reveals a cost structure where operating expenses, including research and development and selling, general, and administrative costs, consume a large portion of gross receipts before arriving at the final profit. Pacira BioSciences generated free cash flow of $108.56M, which indicates a strong capacity to fund ongoing operations, invest in pipeline development, or manage liquidity without relying heavily on external capital markets. The company's margin profile consists of a gross margin of 63.2%, an operating margin of -1.2%, and a profit margin of 1.0%, suggesting that while the core production is highly efficient, operating expenses currently outweigh operating profits to a degree that compresses the final bottom line. On the balance sheet, total cash stands at $238.42M against total debt of $418.20M, creating a net debt position, while the debt-to-equity ratio of 60.34 highlights a leveraged capital structure that relies on borrowed funds to finance its operations. Despite the leverage, the current ratio of 4.54 demonstrates robust short-term liquidity, indicating that the company holds more than four times the current assets necessary to cover its current liabilities. Additionally, the return on equity is 1.0% and the return on assets is 1.5%, metrics that reveal management is currently generating modest returns on the capital deployed, a common characteristic for biopharmaceutical firms in the development or commercialization phase where high reinvestment is required.
Valuation Assessment
Pacira BioSciences trades with a P/E ratio of 140.94 on a trailing twelve-month basis and a forward P/E of 6.34, a stark difference that implies the market expects a dramatic turnaround in earnings performance or that current earnings do not reflect the future potential of the company's pipeline. The price-to-book ratio is 1.34, indicating that the market values the company at a modest premium of 34% over its book value, which suggests investors are pricing in intangible assets like intellectual property rather than just physical book value. Alternative valuation metrics further contextualize the company's price, with a price-to-sales ratio of 1.34 and an EV/EBITDA of 8.65, suggesting the stock is valued roughly at one-third of its sales revenue and offers a multiple that is relatively compressed relative to its EBITDA generation capabilities. The 52-week price range spans from a low of $18.80 to a high of $27.64, and without a specific current price provided in the available facts, the valuation context is defined by this historical volatility range which captures the recent market sentiment. The beta of 0.23 indicates that the stock's price volatility is significantly lower than the broader market, moving with much less intensity than the overall index, which provides a defensive characteristic often seen in smaller-cap biotech names.
Growth & Income
Revenue growth for the year-over-year period stands at 5.1%, while earnings growth is -88.4%, a divergence that implies earnings are shrinking at a much faster rate than revenue, likely due to the high operating expenses mentioned in the financial health section. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all of its earnings into growth initiatives such as research and development rather than distributing cash to shareholders. This reinvestment strategy is typical for a company with a forward P/E of 6.34, where the market anticipates future profitability will drive value rather than current dividend payments. Overall, the growth and income profile is characterized by positive top-line expansion coupled with a significant contraction in profitability, supported by strong free cash flow generation that allows the company to sustain its operations and potential future growth without immediate reliance on equity financing.